A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Public ClinicalTrials.gov record NCT00533702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
Study identification
- NCT ID
- NCT00533702
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2007
- Primary completion
- Apr 30, 2011
- Completion
- Apr 30, 2011
- Last update posted
- Jul 31, 2014
2007 – 2011
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Decatur | Alabama | 35601 | — |
| ImClone Investigational Site | Scottsdale | Arizona | 85258 | — |
| ImClone Investigational Site | Scottsdale | Arizona | 85260 | — |
| ImClone Investigational Site | Fresno | California | 93720 | — |
| ImClone Investigational Site | San Francisco | California | 94109 | — |
| ImClone Investigational Site | Aurora | Colorado | 80045 | — |
| ImClone Investigational Site | Jacksonville | Florida | 32256 | — |
| ImClone Investigational Site | Orlando | Florida | 32806 | — |
| ImClone Investigational Site | Oxford | Mississippi | 38655 | — |
| ImClone Investigational Site | Missoula | Montana | 59806 | — |
| ImClone Investigational Site | Buffalo | New York | 14263 | — |
| ImClone Investigational Site | New York | New York | 10016 | — |
| ImClone Investigational Site | New York | New York | 10021 | — |
| ImClone Investigational Site | Willow Grove | Pennsylvania | 19090 | — |
| ImClone Investigational Site | Dallas | Texas | 75230 | — |
| ImClone Investigational Site | Houston | Texas | 77030 | — |
| ImClone Investigational Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00533702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2014 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00533702 live on ClinicalTrials.gov.